<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04198831</url>
  </required_header>
  <id_info>
    <org_study_id>ZYS2015-03</org_study_id>
    <nct_id>NCT04198831</nct_id>
  </id_info>
  <brief_title>Effect of Acupuncture on Quiescent Crohn's Disease</brief_title>
  <official_title>Effect of Acupuncture on Quiescent Crohn's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Institute of Acupuncture, Moxibustion and Meridian</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Indiana University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Institute of Acupuncture, Moxibustion and Meridian</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To observe the clinical effect of acupuncture on quiescent Crohn's disease
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To observe the effect of acupuncture on maintaining remission of quiescent Crohn's disease
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2015</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of clinical recurrences</measure>
    <time_frame>Week 48</time_frame>
    <description>Defined as CDAI &gt; 150 and increased by ≥70 points or need to adjust drug to control active disease.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean time of recurrence</measure>
    <time_frame>Week 48</time_frame>
    <description>The mean duration of disease recurrence during follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean change of CDAI from baseline</measure>
    <time_frame>Week 12, 24, 36 and 48</time_frame>
    <description>Difference in the mean change of CDAI from baseline between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean change of Inflammatory Bowel Disease Questionnaire (IBDQ)</measure>
    <time_frame>Week 12 and 24</time_frame>
    <description>Quality of life assessment for Crohn's disease. The score ranges from 32 to 224, and the higher the score, the better the outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean change of the Hospital anxiety and depression scale (HADS)</measure>
    <time_frame>Week 12 and 24</time_frame>
    <description>Psychological factors (Anxiety and depression) assessment for CD. The score ranges from 0 to 21, and the higher the score, the worse the outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean change of Crohn's disease endoscopic index of severity (CDEIS)</measure>
    <time_frame>Week 48</time_frame>
    <description>Intestinal inflammation performance. The score ranges from 0 to 44, and the higher the score, the worse the outcome.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>brain structural and functional changes</measure>
    <time_frame>Week 12</time_frame>
    <description>brain functional and structural changes reflected by fMRI</description>
  </other_outcome>
  <other_outcome>
    <measure>Intestinal microbiota</measure>
    <time_frame>Week 12</time_frame>
    <description>Changes in the structure and diversity of fecal microbiota detected by 16S rDNA sequencing.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Inflammatory Bowel Diseases</condition>
  <condition>Crohn Disease</condition>
  <arm_group>
    <arm_group_label>acupuncture group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receiving acupuncture and moxibustion treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sham acupuncture group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Receiving sham acupuncture and sham moxibustion treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>acupuncture</intervention_name>
    <description>Patients receiving acupuncture and mild moxibustion, whom were treated 3 times per week for 12 weeks and followed up for 36 weeks. CV12 and Bilateral ST37, SP6, SP4, LR3, KI3, LI4 and LI11 were selected for acupuncture and bilateral ST25 and ST36 were selected for moxibustion. Hwato acupuncture device was used to blind the subjects, and had the deqi sensation. The surface temperature of acupoints was maintained at 43℃± 1℃ for moxibustion.</description>
    <arm_group_label>acupuncture group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham acupuncture</intervention_name>
    <description>Patients receiving sham acupuncture and sham mild moxibustion, whom were treated 3 times per week for 12 weeks and followed up for 36 weeks. CV12 and Bilateral ST37, SP6, SP4, LR3, KI3, LI4 and LI11 were selected for acupuncture and bilateral ST25 and ST36 were selected for moxibustion. Same Hwato acupuncture device was used to blind the subjects, but do not puncturing into the skin and do not have the deqi sensation. The surface temperature of acupoints was maintained at 37℃± 1℃ for moxibustion.</description>
    <arm_group_label>sham acupuncture group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. aged 16-70;

          2. patients in remission (CDAI &lt; 150);

          3. patients were not taking medication or were only taking one or more of the following
             drugs: [prednisone ≤15mg/d, azathioprine (≤1mg/kg/d), methotrexate (≤15mg/w) or
             mesalazine (≤4g/d)] and prednisone was used for at least 1 month, while azathioprine,
             methotrexate or mesalazine was used for at least 3 months;

          4. those who did not use anti-TNF alpha and other agents within 3 months before entering
             the study;

          5. those who have never experienced acupuncture;

          6. patients signing informed consent.

        Exclusion Criteria:

          1. patients who are recently pregnant or in pregnancy or lactation;

          2. patients with serious organic diseases;

          3. patients diagnosed as psychosis;

          4. patients who take antibiotics, probiotics, traditional Chinese medicine and other
             drugs at the same time, or who suffer from multiple diseases and need to take other
             drugs for a long time, and may affect the observation of the efficacy of this trial;

          5. severe skin diseases (such as erythema nodosum, pyoderma gangrenosum, etc.), eye
             diseases (such as iritis, uveitis, etc.), thromboembolic diseases and other serious
             extraintestinal manifestations;

          6. there are serious intestinal fistula, abdominal abscess, intestinal stenosis and
             obstruction, perianal abscess, gastrointestinal hemorrhage, intestinal perforation and
             other complications;

          7. patients with short bowel syndrome who have undergone abdominal or gastrointestinal
             surgery in the past half a year;

          8. there are skin diseases or defects in the selected area of acupuncture and moxibustion
             that cannot be performed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huangan Wu, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Shanghai Research Institute of Acupuncture and Meridian</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chunhui Bao, MD, PhD</last_name>
    <phone>+862164395973</phone>
    <email>baochunhui789@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Research Institute of Acupuncture and Meridian</name>
      <address>
        <city>Shanghai</city>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chunhui Bao, MD, PhD</last_name>
      <phone>+862164395973</phone>
      <email>baochunhui789@126.com</email>
    </contact>
    <investigator>
      <last_name>Huangan Wu, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 11, 2019</study_first_submitted>
  <study_first_submitted_qc>December 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2019</study_first_posted>
  <last_update_submitted>December 12, 2019</last_update_submitted>
  <last_update_submitted_qc>December 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acupuncture</keyword>
  <keyword>Crohn's disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

